Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.83 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.83 |
| ▸ | LYN | P07948 | 4/20 | 0.83 |
| ▸ | FLT1 | P17948 | 3/20 | 0.83 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.83 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.83 |
| ▸ | FLT4 | P35916 | 2/20 | 0.83 |
| ▸ | PDXK | O00764 | 1/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.83 |
| ▸ | RET | P07949 | 1/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.83 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.83 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.83 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.83 |
| ▸ | AURKA | O14965 | 16/20 | 0.82 |
| ▸ | TEK | Q02763 | 16/20 | 0.82 |
| ▸ | MET | P08581 | 14/20 | 0.82 |
| ▸ | LCK | P06239 | 13/20 | 0.82 |
| ▸ | ABL1 | P00519 | 2/20 | 0.82 |
| ▸ | FGR | P09769 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lucitanib SCHEMBL29363689 | 0.91 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL29375046 | 0.91 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL381394 | 0.91 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL29365836 | 0.91 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| SCHEMBL2746021 | 0.91 | KDR (1.00) | KDRAURKBLYNFLT1AURKA | |
| SCHEMBL2096054 | 0.90 | KDR (0.81) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL30737889 | 0.90 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL26928177 | 0.90 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| Lucitanib SCHEMBL29379692 | 0.90 | KDR (1.00) | KDRAURKBLYNFLT1FGFR1 | |
| SCHEMBL2098716 | 0.88 | KDR (0.77) | KDRAURKBLYNFLT1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513283-B2 | Spiro substituted compounds as angiogenesis inhibitors | ADVENCHEN LABORATORIES, LLC (US) | 2013-08-20 | — | — | US | claimed |
| EP-2125777-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LAB LLC (US) | 2013-04-10 | — | — | EP | claimed |
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2012-06-28 | — | — | US | claimed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | claimed |
| EP-2125777-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | Advenchen Laboratories, LLC (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | claimed |
| WO-2008112408-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | claimed |
| US-8513283-B2 | Spiro substituted compounds as angiogenesis inhibitors | ADVENCHEN LABORATORIES, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513283-B2 | Spiro substituted compounds as angiogenesis inhibitors | ADVENCHEN LABORATORIES, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2125777-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LAB LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2125777-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | Advenchen Laboratories, LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| WO-2008112408-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | TEK, KDR, TIE1 | KDR 2/4885AURKB 247/4885LYN 51/4885 |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | KDR 2/4885AURKB 247/4885LYN 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.